{
    "clinical_study": {
        "@rank": "53908", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver\n      tumor-killing substances to them without harming normal cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in\n      treating patients who have prostate cancer that has not responded to hormone therapy."
        }, 
        "brief_title": "Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer", 
        "completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the antitumor effects of monoclonal antibody huJ591 in patients with\n           progressive androgen-independent prostate cancer.\n\n        -  Determine the biodistribution and dosimetry of this antibody in these patients.\n\n        -  Determine the effect on biodistribution of the delivery sequence of unlabeled vs indium\n           In 111-labeled antibody in these patients.\n\n        -  Determine the HAHA response in patients treated with this regimen.\n\n        -  Correlate the dose of monoclonal antibody huJ591 with antibody-dependent cellular\n           cytotoxicity in these patients.\n\n      OUTLINE: Patients are assigned to one of two treatment groups.\n\n        -  Group I: Patients receive monoclonal antibody huJ591 IV followed by indium In 111\n           monoclonal antibody huJ591 on day 1.\n\n        -  Group II: Patients receive monoclonal antibody huJ591 concurrently with indium In 111\n           monoclonal antibody huJ591 as in group I.\n\n      Treatment in both groups repeats every 3 weeks for 4 courses in the absence of disease\n      progression or unacceptable toxicity.\n\n      Patients are followed for 4 weeks and then monthly for 3 months.\n\n      PROJECTED ACCRUAL: A total of 14 patients (7 per treatment group) will be accrued for this\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed prostate cancer\n\n          -  Disease progression after prior castration\n\n               -  At least 3 rising PSA levels at least 1 week apart OR 2 rising levels at least 4\n                  weeks apart\n\n          -  New osseous lesions on bone scan and/or more than 25% increase in bidimensionally\n             measurable soft tissue disease or appearance of new sites of disease by CT scan or\n             MRI\n\n          -  Testosterone no greater than 50 ng/mL\n\n               -  Medical therapy (e.g., gonadotropin-releasing hormone analogues) to maintain\n                  castrate level of testosterone should continue in the absence of surgical\n                  orchiectomy\n\n          -  Progression of disease after discontinuation of prior anti-androgen therapy\n\n          -  No requirement for palliative therapy within the past 12 weeks\n\n          -  No active CNS or epidural primary tumor OR active CNS or epidural metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC greater than 3,500/mm3\n\n          -  Platelet count greater than 100,000/mm3\n\n        Hepatic:\n\n          -  Bilirubin less than 1.5 mg/dL\n\n          -  Gamma-glutamyl-transferase less than upper limit of normal (ULN)\n\n          -  AST less than ULN\n\n          -  PT less than 14 seconds\n\n          -  No prior autoimmune hepatitis\n\n        Renal:\n\n          -  Creatinine less than 1.5 mg/dL OR\n\n          -  Creatinine clearance greater than 60 mL/min\n\n        Cardiovascular:\n\n          -  No clinically significant cardiac disease (New York Heart Association class III or\n             IV)\n\n        Pulmonary:\n\n          -  No severe debilitating pulmonary disease\n\n        Other:\n\n          -  Fertile patients must use effective contraception\n\n          -  No active uncontrolled infection or infection requiring IV antibiotics\n\n          -  No prior autoimmune disease\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior murine protein for diagnostic or therapeutic purposes\n\n          -  No other concurrent anticancer immunotherapy\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy and recovered\n\n          -  No concurrent anticancer chemotherapy\n\n        Endocrine therapy:\n\n          -  See Disease Characteristics\n\n          -  No concurrent anticancer hormonal therapy\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n          -  Concurrent radiotherapy to localized sites of disease (e.g., bone) allowed if the\n             site does not contain sole measurable lesion\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  No concurrent surgery\n\n        Other:\n\n          -  Recovered from all prior therapy\n\n          -  At least 4 weeks since prior therapeutic investigational anticancer drugs\n\n          -  At least 4 weeks since prior participation in therapeutic clinical trial with an\n             experimental drug\n\n          -  No prior diagnostic ProstaScint, Myoscint, or Oncoscint scans\n\n          -  No other concurrent therapeutic investigational anticancer agents\n\n          -  No concurrent participation in other therapeutic clinical trial with an experimental\n             drug"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "September 13, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00024232", 
            "org_study_id": "MSKCC-01030", 
            "secondary_id": [
                "CDR0000068903", 
                "NCI-G01-2013"
            ]
        }, 
        "intervention": {
            "intervention_name": "monoclonal antibody huJ591", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "keyword": [
            "stage IV prostate cancer", 
            "recurrent prostate cancer"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-01030"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pilot Trial of Humanized Monoclonal Antibody J591 in Patients With Progressive Androgen-Independent Prostate Cancer", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Michael Morris, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00024232"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}